LEFF A: Regulation of leukotrienes in the management of asthma: biology and clinical therapy. Ann. Rev. Med. (2001) 52:1-14.
BUSSE W, McGILL A, HORWITZ J: Leukotriene pathway inhibitors in asthma and chronic obstructive pulmonary disease. Clin. Exp. Aller. (1999) 29:110-115.
SHARON P, STENSO W: Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammation bowel disease. Gastroenterology (1984) 86:453-460.
KILFEATHER S: 5-lipoxygenase inhibitors for the treatment of COPD. Chest (2002) 121:197S-200S.
GHOSH J, MYERS C: Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. Biochem. Biophys. Res. Commun. (1997) 235:418-423.
ISRAEL E: Moderating the inflammation of asthma: inhibiting the production or the action of products of the 5-lipoxygenase pathway. Ann. Allergy (1994) 279-284.
DIXON R, DIEHL R, OPAS E et al.: Requirement of a 5-lipoxygenase activating proteine for leukotriene synthesis. Nature (1990) 343:282-284.
MILLER D, GILLARD J, VICKERS P et al.: Identification and isolation of a membrane protein necessary for leukotriene production. Nature (1990) 343:278-281.
PETERS-GOLDEN M, BROCK T: Intracellular compartmentalization of leukotriene synthesis: unexpected nuclear secrets. FEBS Lett. (2001) 487:323-326.
HAMMARGERG T, PROVOST P, PERSSON B et al.: The N-terminal domain of 5-lipoxygenase binds calcium and mediates calcium stimulation of enzyme activity. J. Biol. Chem. (2000) 275:38787-38793.
CHEN X, FUNK C: The N-terminal 'β-barrel' domain of 5-lipoxygenase is essential for nuclear membrane translocation. J. Biol. Chem. (2001) 276:811-818.
YOUNG R: Inhibitors of the 5-lipoxygenase: a therapeutic potential yet to be fully realized? Eur. J. Med. Chem. (1999) 34:671-685.
LEWIS R, AUSTEN K, SOBERMAN R: Leukotrienes and other products of the 5-lipoxygenase pathway. N. Engl. J. Med. (1990) 323:645-655.
LAM B, PENROSE I, FREEMAN G et al.: Expression cloning of a cDNA for human leukotriene C4 synthase, an integral membrane proteine conjugating reduced glutathione to leukotriene A. Proc. Natl. Acad. Sci. USA (1994) 91:7663-7667.
TATE S, MEISTER A: γ-Glutamyl transpeptidase: catalytic, structural and functional aspects. Mol. Cell Biochem. (1981) 39:357-368.
LEE C, LEWIS R, COREY E et al.: Conversion of leukotriene D4 to leukotriene E4 by a dipeptidase released from the specific granule of human polymorphonuclear leucocytes. Immunology (1983) 48:27-35.
RADMARK O: The molecular biology and regulation of 5-lipoxygenase. Am. J. Resp. Crit. Care Med. (2000) 161:S11-S15.
RIENDEAU D, FALGUEYRET J, GUAY J et al.: Pseudoperoxidase activity of 5-lipoxygenase stimulated by potent benzofuranol and N-hydroxyurea inhibitors of the lipoxygenase reaction. Biochem. J. (1991) 274:287-292.
OCHI K, YOSHIMOTO T, YAMAMOTO S. TANIGUCHI K, MIYAMOTO T: Arachidonate 5-lipoxygenase of guinea-pig peritoneal polymorphonuclear leukocytes. Activation by adenosine 5′-triphosphate. J. Biol. Chem. (1983) 258:5754-5758.
ROUZER C, KARGMAN S: Translocation of 5-lipoxygenase in human leukocytes challenged with ionophore A23187. J. Biol. Chem. (1988) 263:10980-10988.
YOKOMIZO T, IZUMI T, CHANG K et al.: A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature (1997) 387:620-624.
HEISE C, O'DOWD B, FIGUEROA D et al.: Characterization of the human cysteinyl leukotriene 2 receptor. J. Biol. Chem. (2000) 275:30531-30536.
LYNCH K, O'NEILL G, LIU Q et al.: Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature (1999) 399:789-793.
GRONERT K, MARTINSSON T, RAVASI S et al.: Selectivity of recombinant human leukotriene D(4), leukotriene B(4) and lipoxin A(4) receptors with aspirin-triggered 15-epi-LXA(4) and regulation of vascular and inflammatory responses. Am. J. Pathol. (2001) 158:3-9.
CAMP R, MALLET A, WOOLLARD P et al.: The identification of hydroxy fatty acids in psoriatic skin. Prostaglandins (1983) 26:431-447.
DAHLEN S, HEDQVIST P, HAMMARSTORM S et al.: Leukotrienes are potent constrictor of human bronchi. Nature (1980) 228:484-486.
TSUNODA H, ABE S, SAKUMA Y et al.: Involvement of leukotriene C4 in PAF-induced death in mice. Leukotrienes and Essential Fatty Acids (1990) 39:291-294.
GOLDENBERG M, SUBERS E: The reactivity of rat isolated gastrointestinal tissues to leukotrienes. Eur. J. Pharmacol. (1982) 78:463-466.
MAGOUS R, BALI J, ROSSI J et al.: Lukotrienes stimulate acid secretion from isolated gastric parietal cells. Biochem. Biophy. Res. Com. (1983) 114:897-900.
RIOUX N, CASTONGUAY A: Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents. Carcinogenesis (1998) 19:1393-1400.
DE LEVAL X, JULEMONT F, DELARGE J et al.: New trends in dual 5-LOX/COX inhibition. Curr. Med. Chem. (2002) 9:941-962.
HENNIG R, DING X, TONG W et al.: 5-lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am. J. Pathol. (2002) 161:421-428.
MYER C, GHOSH J: Lipoxygenase inhibition in prostate cancer. European Urology (1999) 35:395-398.
SHUREIQI I, LIPPMAN S: Lipoxygenase modulation to reverse carcinogenesis. Cancer Res. (2001) 61:6307-6312.
FUJIMURA M, SAKAMOTO S, KAMINO Y et al.: Effect of a leukotriene antagonist, ONO-1078, on bronchial hyper-responsiveness in patients with asthma. Respir. Med. (1993) 87:133-138.
NATHAN R, BERNSTEIN J, BIELORY L et al.: Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. J. Allergy Clin. (1998) 12:935-942.
IHAKU D, CAMERON L, SUZUKI M et al.: Montelukast, a leukotriene receptor antagonist, inhibits the late airway response to antigen, airway cosinophilia and IL-5 expressing cells in Brown-Norway rats. J. Allergy Clin. (1999) 104:1075-1080.
GOLDBERG B, STERN A: Production of superoxide anion during the oxidation of hemoglobin by menadione. Biochem. Biophys. Acta (1976) 437:628-632.
GUINDON Y, GIRARD Y, MAYCOCK A et al.: L-651,392: a novel, potent and selective 5-lipoxygenase inhibitor. Advances in Prostaglandin Thromboxane and Leukot. Res. (1987) 17A:554-557.
BRUNEAU P, DELVARE C, EDWARDS M et al: Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J. Med. Chem. (1991) 34:1028-1036.
BELANGER P, MAYCOCK A, GUINDON Y et al.: L-656,224 (7-chloro- 2-[(4-methoxyphenyl)methyl]-3- methyl- 5-propyl-4-benzofuranol): a novel, selective, orally-active 5-lipoxygenase inhibitor. Can. J. Physiol. Pharmacol. (1987) 65:2441-2448.
TATERSON J, RANDALL R, REYNOLDS C et al.: Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: biochemical assessment in vitro and ex vivo. Br. J. Pharmacol. (1988) 94:528-539.
SUMMERS J, GUNN B, MARTIN J et al.: Structure-activity analysis of a class of orally-active hydroxamic acid inhibitors of leukotriene biosynthesis. J. Med. Chem. (1988) 31:1960-1964.
WENZEL S, KAMADA A: Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma. Ann. Pharmacotherapy (1996) 30:858-864.
BROOKS D, STEWART A, BASHA A et al.: 206th ACS Nat. Meeting, Aug 22-27, Chicago (1993) Abst. Medi. 41.
SCOTT A, MALLOY E, WU W et al.: N-(5-substitued) thiophene-2-alkylsulfonamides as potent inhibitors of 5-lipoxygenase. Biorg. Med. Chem. (1997) 5:779-786.
BIRD, BRUNEAU P, CRAWLEY G et al.: (Methoxyalkyl)thiazoles: a new series of potent, selective and orally-activc 5-lipoxygenase inhibitors displaying high enantioselectivity. J. Med. Chem. (1991) 34:2176-2186.
CRAWLEY G, DOWELL R, EDWARDS P et al.: Methoxytetrahydropyrans. A new series of selective and orally potent 5-lipoxygenase inhibitors. J. Med. Chem. (1992) 35:2600-2609.
BIRD T, BRUNEAU P, CRAWLEY G et al.: (Methoxyalkyl)thiazoles: a new series of potent, selective and orally-active 5-lipoxygenase inhibitors displaying high enantioselectivity J. Med. Chem. (1991) 34:2176-21860.
DUCHARME Y, BRIDEAU C, DUBE D et al.: Naphthalenic lignan lactones as selective, nonredox 5-lipoxygenase inhibitors. Synthesis and biological activity of (methoxyalkyl)thiazole and methoxytetrahydropyran hybrids. J. Med. Chem. (1994) 37:512-518.
MILLER D, GILLARD P, VICKERS S et al.: Identification and isolation of a membrane protein necessary for leukotriene production. Nature (1990) 343:278-281.
MUSSER J, CHAKRABORTY U, SCIORTINO S et al.: Substituted arylmethyl phenyl ethers. 1. A novel series of 5-lipoxygenase inhibitors and leukotriene antagortists. J. Med. Chem. (1987) 30:96-104.
PRASIT P, BELLEY M, BLOUIN M et al.: A new class of leukotriene biosynthesis inhibitor: the development of MK-0591. J. Lipid Med. (1993) 6:239-244.
HAMILTON A, WATSON R, WYILE G et al.: Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005. Thorax (1997) 52:348-354.
DEPRE M, VAN HECKEN A, VERBESSELT R et al.: Biochemical activity, pharmacokinetics and tolerability of tepoxalin, a cyclooxygenase/5-lipoxygenase inhibitor, in man. Int. J. Clin. Pharmacol. Res. (1996) 16:1-8.
HARRIS R, BATT D, GALBRAITH W et al.: Topical anti-inflammatory activity of DuP 654, a 2-substituted 1-naphthol. Agents and Actions (1989) 27(Suppl.):297-299.
CHIA Y, JONG H, SON K et al.: Effects of naturally-occurring prenylated flavonoids on enzymes metabolizing arachidonic acid: cyclooxygenases and lipoxygenases. Biochem. Pharmacol. (2001) 62:1185-1191.
